52 TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 chromatography, robotic liquid handling, and flow chemistry systems hold promise for the future. In ADC applications, these approaches could reduce manual handling, minimize contamination risks, and improve worker safety when dealing with highly potent payloads. Closed-system processing, where therapeutics are handled entirely within sealed environments, may also help ensure sterility and reduce product loss. While not yet a widespread market trend, these innovations could become more relevant as ADC manufacturing scales or as process intensification becomes a focus. Linked closely to these developments is the concept of continuous manufacturing, where automation and integrated, closed processes enable a streamlined, uninterrupted flow of materials. Unlike traditional batch processing, continuous manufacturing offers a streamlined, uninterrupted flow of materials, reducing processing times and minimizing variability. This approach holds the potential to greatly improve throughput and lower production costs, making ADC therapies more accessible and affordable. Another promising avenue is the integration of microfluidics. These technologies help better control chemical reactions at a microscopic scale, making it easier to synthesize complex payloads with unprecedented purity and yield. By reducing the use of reagents and side reactions, microfluidics contributes to a more sustainable and cost-effective manufacturing process. Also, the scalability of microfluidic systems makes them a good option for both smallscale development and large-scale commercial production. Enzymatic synthesis is becoming more popular as a greener and more efficient alternative to traditional chemical synthesis. With high selectivity and catalytic activity, enzymes can help achieve complex reactions under mild conditions, reducing the need for harsh solvents and reagents. This approach reduces environmental impact and makes purification processes simpler, leading to cost savings and improved product quality. The increasing use of computational chemistry and artificial intelligence (AI) is also revolutionizing payload design and synthesis. AI-driven algorithms can predict reaction pathways, optimize process parameters, and identify potential impurities, accelerating development timelines and improving process robustness. Using these powerful tools, researchers can streamline payload manufacturing, reduce development costs, and ensure the consistent production of high-quality ADC components. These innovative strategies, combined with advancements in linker technology and conjugation chemistries, help to make the future of ADC therapies more efficient and sustainable. The future promise of ADCs The next wave of ADC innovation is likely to be driven by formats and payload strategies already in clinical development. Current research and early clinical trials are exploring: - Next-generation bioconjugation methods, including advanced enzyme-mediated and photochemical methods, enable more precise, site-specific conjugation. - Bispecific ADCs, designed to engage two distinct antigens for improved targeting. - Dual-payload ADCs, carrying two different cytotoxic agents to overcome resistance or target multiple mechanisms. - Oligonucleotide or peptide conjugates, broadening therapeutic applications beyond traditional smallmolecule payloads. These approaches represent the most immediate trends expected to reach the market in the near to mid-term. Other novel conjugates, such as steroidlinked ADCs, are also under investigation. Innovative linker technologies (such as stimuliresponsive and biodegradable linkers), novel payload classes, and AI-assisted design will continue to expand the therapeutic potential of ADCs3. Expert contract development and manufacturing organizations (CDMOs) with bioconjugation and payload manufacturing expertise will remain critical partners in translating these innovations into commercial products, with a focus on patient safety alongside robust process development, scale-up, and quality control. In essence, CDMOs act as crucial enablers, empowering researchers and pharmaceutical companies to overcome the challenges of ADC development and deliver transformative therapies to patients. References 1. https://www.statista.com/outlook/hmo/ pharmaceuticals/worldwide 2. https://www.cas.org/resources/cas-insights/ unveiling-potential-antibody-drug-conjugate 3. https://journals.sagepub.com/doi/full/10.1177/1758 8359241309461 AXPLORA JIN SEOK HUR Director of ADC Platform Management Axplora
RkJQdWJsaXNoZXIy MjY2OTA4MA==